|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 100 DAINGERFIELD ROAD |
Address2 | 3rd FLOOR |
City | ALEXANDRIA |
State | VA |
Zip Code | 22314 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 27478-12
|
||||||||
|
6. House ID# 303540000
|
TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Anne Cassity |
Date | 1/21/2025 5:21:35 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
S. 2666, the E-Prescribing Parity for Controlled Substances Act;
Remote Prescribing of Controlled Substances & Dispensing of Controlled Substances;
H.R. 9886/S.5271, the BUPE for Recovery Act;
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
Steve |
Postal |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act;
S. 2052, the Protect Patient Access to Pharmacies Act;
H.R. 2880, the Protecting Patients Against PBM Abuses Act;
H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act;
S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act;
H.R. 2816, the PBM Sunshine and Accountability Act;
H.R. 3281, the Transparent PRICE Act;
H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act;
H.R. 3561, the PATIENT Act;
S. 1967, the Patients Before Middlemen (PBM) Act;
S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act;
S. 2405, the Strengthening Pharmacy Access for Seniors Act;
S. 2973, the Modernizing and Ensuring PBM Accountability Act;
H.R. 5378, the Lower Costs, More Transparency Act;
H.R.5385, the Medicare PBM Accountability Act;
H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes;
H.R. 5400 / S. 2436, the NO PBMs Act;
S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023;
Request for Information for "Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act" (IRA; P.L. 117-169);
Comments for "Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025" (IRA, P.L. 117-169);
Comments for Final Rule Document 2022-09375, "Medicare Program, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs..." (87 FR 27704);
Comments for "Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies" (CMS-2024-0006);
Request for Information for Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft;
H.R.4366, the Consolidated Appropriations Act, 2024
H.R.2882, the Further Consolidated Appropriations Act, 2024
Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement;
Comments to CMS on the implementation of Medicare Part D vaccine coverage under the Inflation Reduction Act (IRA; P.L. 117-169);
Comments to CMMI on the Importance of Implementing Reasonable Reimbursement Guardrails for
Pharmacies in the Medicare $2 Drug List Model based on the Executive Order on Lowering Prescription Drug Costs for Americans;
Comments to HHS and CMS on 2024 NADAC Methodology Changes;
Comment to CMS on "Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections
1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer
Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027.";
H.R. 9096, the Pharmacists Fight Back Act;
Long Term Care at Home Pharmacy Services in Medicare;
Regulating fair and common-sense contracting guardrails between Part D plans/PBMs, and
pharmacies;
Comments to CMS on Proposed Rule Re: Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments [CMS-1807-P];
H.R.4758, the Accelerating Kids Access to Care Act;
H.R. 8107, the Ensuring Access to Medicaid Buy-in Programs Act of 2024;
Comments to CMS on Draft Guidance Re: Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027;
Request for Information to CMS on "Medicare $2 Drug list Model" (Executive Order 14087 of October 14, 2022);
H.R.5074/S.5410, the Kidney PATIENT Act;
H.R.4104/S.1976, the Preserving Patient Access to Home Infusion Act;
H.R.10545, the American Relief Act, 2025;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Small Business Administration (SBA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
Steve |
Postal |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023;
H.R. 2679, the Pharmacy Benefits Manager Accountability Act;
H.R. 3008, the Drug Shortage Prevention Act;
S. 1339, the Pharmacy Benefits Manager Reform Act;
S. 1542 / H.R. 6283, the Delinking Revenue from Unfair Gouging Act;
H.R. 1173, the Patients Right to Know Their Medication Act of 2023;
Proposed rule for Medication Guides: Patient Medication Information (Docket No. FDA-2019-N-5959);
Implementation of Public Law 113-54, the Drug Quality and Security Act;
Draft Guidance for Industry, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act, (Docket No. FDA-2015-D-3517);
H.R. 5400 / S. 2436, the NO PBMs Act;
S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023;
Request for Information for "Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act" (Docket No. FDA-2023-N-4806);
Request for Information on Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft;
H.R.4366, the Consolidated Appropriations Act, 2024;
H.R.2882, the Further Consolidated Appropriations Act, 2024;
Comments on implementation and enforcement of recent changes to USP Chapter
<797>, regarding the Compounded Sterile Preparations (CSPs) in Category 3 to the FDA;
Comments to FDA on "Agency Information Collection Activities; Proposed Collection; Comment Request; Proposed Small Dispensers Assessment Under the Drug Supply Chain Security Act" [Docket No.FDA-2024-N-0668];
Comments to FDA on " Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act"[Docket No. FDA-2023-N-0061];
H.R.9096, the Pharmacists Fight Back Act;
Comments to FDA on Docket No. FDA-2023-N-4806 - Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food,
Drug, and Cosmetic Act; Establishment of a Public Docket; Request for Information and
Comment.
Comments to FDA on "Pharmacy Compounding Advisory Committee's Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List Revisions to the Withdrawn or Removed List [Docket No. FDA-2024-N-4188]";
Comment to FDA on "Pharmaceutical Distribution Supply Chain; Drug Supply Chain Security" [Docket No. FDA-2024-N-3675];
Comment to FDA on "Opposition to Novo Nordisk and Eli Lillys Requests to Place GLP-1 Medications on the Demonstrably Difficult to Compound List" [Docket No. FDA-2015-N-0030];
H.R.10239/S.5368,the Ending Drug Shortages Act;
H.R.10362, the PBM Act of 2024;
H.R.10545, the American Relief Act, 2025;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
Steve |
Postal |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 4794, the Dietary Supplement Access Act;
H.R.8147, Repealing Big Brother Overreach Act;
H.R. 9278, To amend section 5336 of title 31, United States Code, to provide existing small businesses with an additional year to file beneficial ownership information, and for other purposes;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of, Internal Revenue Service (IRS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
S. 127, the PBM Transparency Act;
S. 113, the Prescription Pricing for the People Act;
Request for Information on "Consolidation in Health Care Markets [Docket No. ATR 102]";
H.R.10362, the PBM Act of 2024;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Federal Trade Commission (FTC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
TRICARE pharmacy network changes;
H.R. 2670, National Defense Authorization Act for Fiscal Year 2024;
H.R. 4638, National Defense Authorization Act for Fiscal Year 2025;
S.4638, National Defense Authorization Act for Fiscal Year 2025;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Defense - Dept of (DOD)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY24 appropriations language request to fund FTC enforcement of the Robinson-Patman Act;
FY24 appropriations report language to address TRICARE pharmacy network;
Labor, Health and Human Services, Education, and Related Agencies Appropriations Bill, FY 2025;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Kaitlin |
Krell |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TEC
16. Specific lobbying issues
Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anne |
Cassity |
|
|
|
Ronna |
Hauser |
|
|
|
Kaitlin |
Krell |
|
|
|
Steve |
Postal |
|
|
|
David |
Weissman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Comments to OTR on CBP interpretive rule regarding on 19 U.S.C. 1304 and 19 C.F.R. Part 134 titled "Pharmacy Concerns Regarding U.S. Customs and Border Protection Ruling on Prescription Marking for Country of Origin (COO)";
17. House(s) of Congress and Federal agencies Check if None
U.S. Customs & Border Protection, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronna |
Hauser |
|
|
|
Steve |
Postal |
|
|
|
Anne |
Cassity |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |